Literature DB >> 22683595

Cost of readmission: can the Veterans Health Administration (VHA) experience inform national payment policy?

Jason M Hockenberry1, James F Burgess, Justin Glasgow, Mary Vaughan-Sarrazin, Peter J Kaboli.   

Abstract

CONTEXT: Scrutiny of hospital readmissions has led to the development and implementation of policies targeted at reducing readmission rates.
OBJECTIVE: To assess whether historic hospital readmission rates predict risk-adjusted patient readmission and to measure the costs of readmission, thus informing reimbursement policies under consideration by non-Veterans Health Administration payers. DESIGN, SETTINGS, AND PARTICIPANTS: Multivariable hospital-fixed effects regression analyses of patients admitted to 129 Veterans Health Administration hospitals between 2005 and 2009 for 3 common conditions, acute myocardial infarction (AMI), community-acquired pneumonia (CAP), and congestive heart failure (CHF). MAIN OUTCOME MEASURES: We examined whether previous hospital readmission rates predicted risk-adjusted readmission or 30-day episode cost of care for subsequent patients. We then examined the 30-day inpatient hospitalization episode cost differences between those who had a readmission in the episode and those who did not.
RESULTS: Hospital readmission rates in the previous quarter are not predictive of individual patient risk-adjusted readmission or of patients' inpatient hospitalization episode cost in the subsequent quarter. Relative to those who were not readmitted within 30 days of index visit discharge, readmitted patients had 30-day episode costs that were 53.3% (P<0.001), 82.8% (P<0.001), and 79.8% (P<0.001) higher for AMI, CAP, and CHF hospitalization episodes, respectively.
CONCLUSIONS: Previous hospital readmission rates are poor predictors of readmission for future individual patients, therefore, policies using these measures to guide subsequent reimbursement are problematic for hospitals that are financially constrained. Our findings indicate current diagnosis related group payments would need to be raised by 10.0% for AMI, 11.5% for CAP, and 16.6% for CHF if these are to become 30-day bundled payments.

Entities:  

Mesh:

Year:  2013        PMID: 22683595     DOI: 10.1097/MLR.0b013e31825c2fec

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  6 in total

1.  Innovative Payment Mechanisms in Maryland Hospitals: An Empirical Analysis of Readmissions under Total Patient Revenue.

Authors:  Karoline Mortensen; Chad Perman; Jie Chen
Journal:  Healthc (Amst)       Date:  2014-09-01

Review 2.  Patient Characteristics Predicting Readmission Among Individuals Hospitalized for Heart Failure.

Authors:  Melissa O'Connor; Christopher M Murtaugh; Shivani Shah; Yolanda Barrón-Vaya; Kathryn H Bowles; Timothy R Peng; Carolyn W Zhu; Penny H Feldman
Journal:  Med Care Res Rev       Date:  2015-07-14       Impact factor: 3.929

3.  Readmission after neurosurgical intervention in epilepsy: A nationwide cohort analysis.

Authors:  Churl-Su Kwon; Parul Agarwal; Varsha Subramaniam; Mandip Dhamoon; Madhu Mazumdar; Anusha Yeshokumar; Fedor Panov; Saadi Ghatan; Nathalie Jetté
Journal:  Epilepsia       Date:  2019-12-02       Impact factor: 5.864

4.  Association of Post-discharge Service Types and Timing with 30-Day Readmissions, Length of Stay, and Costs.

Authors:  Hyo Jung Tak; Andrew M Goldsweig; Fernando A Wilson; Andrew W Schram; Milda R Saunders; Michael Hawking; Tanush Gupta; Cindy Yuan; Li-Wu Chen
Journal:  J Gen Intern Med       Date:  2021-05-13       Impact factor: 6.473

5.  Examining Characteristics of Hospitalizations in Heart Failure Patients: Results from the 2009 All-payer Data.

Authors:  Lufei Young; Carol Gilbert; Jungyoon Kim; Yaewon Seo; Fernando A Wilson; Li-Wu Chen
Journal:  J Fam Med Dis Prev       Date:  2016-06-28

6.  Unplanned 30-day readmission rates in patients undergoing endo-urological surgeries for upper urinary tract calculi.

Authors:  Manoj Kumar; Siddharth Pandey; Ajay Aggarwal; Deepanshu Sharma; Gaurav Garg; Samarth Agarwal; Ashish Sharma; Satyanarayan Sankhwar
Journal:  Investig Clin Urol       Date:  2018-08-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.